Related Experiment Video
Updated: Feb 5, 2026

Comparable Decellularization of Fetal and Adult Cardiac Tissue Explants as 3D-like Platforms for In Vitro Studies
Published on: March 21, 2019
Why do some ME/CFS patients benefit from treatment with sodium dichloroacetate, but others do not?
1Gent University, Belgium.
Abstract:
Myalgic Encephalopathy/Chronic Fatigue Syndrome (ME/CFS) is an enigmatic disease the pathogenesis of which remains elusive. Pragmatic proof-of-principle of the hypothetical mechanisms causing the clinical symptoms has been delivered, but it is hard to explain why some patients do respond favourably to treatment with sodium dichloroacetate (DCA), which enhances the activity of the mitochondrial enzyme pyruvate dehydrogenase, but other patients experience no benefit from this substance. In a prospective trial including 35 ME/CFS patients, logistic regression analysis with stepwise elimination has identified 6 pre-treatment characteristics allowing for the differentiation between responders (n = 13) and non-reponders (n = 22) with high accuracy (P < 0.0001; area under the ROC-curve = 0.92). A formula was derived generating the probability of belonging to the group of responders. This finding may assist in selecting ME/CFS patients suitable for treatment with DCA, but requires further studies as to the predictive capacity of the derived formula.
Insights
Researchers identified six pre-treatment characteristics to predict which Myalgic Encephalencephalopathy/Chronic Fatigue Syndrome (ME/CFS) patients respond to sodium dichloroacetate (DCA) treatment. This may help personalize ME/CFS therapy by identifying suitable candidates for DCA.
Area of Science:
- Biochemistry
- Immunology
- Neuroscience
Background:
- Myalgic Encephalopathy/Chronic Fatigue Syndrome (ME/CFS) pathogenesis remains unclear.
- Sodium dichloroacetate (DCA) shows variable efficacy in ME/CFS patients.
- DCA enhances mitochondrial pyruvate dehydrogenase activity.
Purpose of the Study:
- To identify predictors of response to sodium dichloroacetate (DCA) in ME/CFS patients.
- To differentiate between ME/CFS patients who respond and those who do not respond to DCA.
- To develop a predictive model for DCA treatment suitability in ME/CFS.
Main Methods:
- Prospective trial involving 35 ME/CFS patients.
- Logistic regression analysis with stepwise elimination.
- Receiver Operating Characteristic (ROC) curve analysis to assess predictive accuracy.
Main Results:
- Six pre-treatment characteristics accurately differentiated responders from non-responders (P < 0.0001, AUC = 0.92).
- A predictive formula was derived to estimate the probability of treatment response.
- 13 patients responded to DCA, while 22 did not.
Conclusions:
- Pre-treatment characteristics can predict DCA response in ME/CFS patients.
- The derived formula may aid in selecting appropriate candidates for DCA therapy.
- Further studies are needed to validate the predictive capacity of the formula for ME/CFS treatment.
Related Concept Videos
Benefits of Self-Esteem
Regulation of Sodium and Potassium
Sodium Regulation
Sodium ions make up approximately 90% of extracellular cations, with a normal blood plasma concentration of 136–148 mEq/L. A decrease in blood volume and pressure triggers the release of renin from granular cells in the juxtaglomerular complex (JGC), primarily...
Roles of Electrolytes: Sodium and Potassium
Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Reduction of Alkynes to trans-Alkenes: Sodium in Liquid Ammonia
When dissolved in liquid ammonia, an alkali metal, such as sodium,...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

